Billionaire Philippe Laffont's investment firm Coatue Management closed its CoreWeave holdings during the fourth quarter of 2025, realizing approximately 80% gains on the AI infrastructure company since its March 2025 initial public offering. The portfolio adjustment reflects a strategic reallocation of capital as the firm evaluates evolving opportunities across its investment landscape.
Simultaneously, Coatue established a new position in Moderna by acquiring 200,000 shares of the biotechnology company. The timing of the Moderna investment preceded a significant rally in the stock, which appreciated nearly 50% during January 2026. Industry analysts attribute Moderna's momentum to the company's strategic pivot toward long-term growth initiatives, including its respiratory vaccine franchise and several pipeline candidates spanning oncology and rare disease treatments.
The portfolio moves underscore the dynamic nature of hedge fund positioning in response to market conditions and company-specific developments. Coatue Management's exit from the artificial intelligence sector investment and entry into the biotechnology space reflects broader portfolio rebalancing strategies employed by institutional investors navigating shifting market themes and valuations.